Job alerts from Nurix Therapeutics
Never miss new job openings
No, I'm not interested
bell icon

Nurix was founded by internationally recognized experts in the ubiquitin-proteasome (UPS) field and received its initial funding from leading life science investors Third Rock Ventures and The Column Group. Nurix recently entered into a multi-year collaboration with Gilead and Sanofi focused on developing bi-functional molecules to degrade protein targets as novel therapeutics. Additionally, Nurix has a strong internal drug discovery pipeline focused on oncology, immunology and inflammation. Nurix plans to advance two molecules into clinical trials in early 2021.

Company - Private
Small
San Francisco, CA, 94102
Scientific Research & Development Firms
2012
See what companies are similar to Nurix Therapeutics
Scientific Research & Development Firms
Small size
Scientific Research & Development Firms
Small size
You comment as